^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Basal Cell Carcinoma

    Related cancers:
    18d
    Comparative Molecular Profiling of Basal Cell Carcinomas in Sun-Exposed and Anogenital Regions. (PubMed, Int J Gynecol Pathol)
    Despite histologic similarity, anogenital BCC demonstrates a distinct molecular profile, suggesting an alternative pathogenesis. Further genomic studies are warranted.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • FGFR3 (Fibroblast growth factor receptor 3) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
    |
    TP53 mutation • PDGFRA mutation
    |
    Oncomine Precision Assay
    19d
    BCC-AI: AI-Based Risk Classification and Histopathological Subtype Prediction of Basal Cell Carcinoma Using Dermoscopic Images (clinicaltrials.gov)
    P=N/A, N=2500, Recruiting, Istanbul Training and Research Hospital
    New trial
    20d
    Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Ohio State University Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=40 --> 4 | Trial primary completion date: Dec 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    UD TGFbetai NK cells
    20d
    Dynamic S-palmitoylation of glioma-associated oncogene 1 regulates the incidence and progression of Sonic Hedgehog medulloblastoma. (PubMed, Cell Death Dis)
    As a result, conditional knockout of Zdhhc13 in cerebellar granule neuron precursors (GNPs) significantly alleviates the severity of MBSHH induced by constitutively active Smoothened (Smo-M2) overexpression and markedly extends overall survival, whereas knockout of Abhd17a increases the incidence of MBSHH induced by Patched-1 ablation, rather than its progression. Together, these findings uncover the dynamic regulation of GLI1 palmitoylation and depalmitoylation by the ZDHHC13 and ABHD17A and subsequent GLI1 stabilization and destabilization as a hitherto uncharacterized mechanism controlling SHH/GLI1 signaling and may provide additional targets for therapeutic intervention of MBSHH.
    Journal
    |
    PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1)
    23d
    Melanoma Colonizing Basal Cell Carcinoma: A Rarely Described Entity. (PubMed, Am J Dermatopathol)
    This case illustrates the diagnostic complexity and clinical effect of BCC-melanoma collision/colonization tumors. Prognosis is dictated by the melanoma component, underscoring the need for meticulous histopathologic evaluation and immunohistochemistry in guiding patient management.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A)
    23d
    DP-SKIN: Digital Phenotyping of Psychological Distress in Skin Cancer Patients (clinicaltrials.gov)
    P=N/A, N=500, Completed, West China Hospital
    New trial
    23d
    Study of Intralesional FLD-103 in Subjects With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P1, N=48, Recruiting, Feldan Therapeutics
    New P1 trial • First-in-human
    25d
    MITOSKIN: Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (clinicaltrials.gov)
    P=N/A, N=119, Completed, University Hospital, Bordeaux | Recruiting --> Completed | N=200 --> 119
    Trial completion • Enrollment change
    26d
    Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=81, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting | N=200 --> 81 | Trial completion date: Jul 2026 --> Apr 2027 | Trial primary completion date: Jul 2026 --> Apr 2027
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    27d
    SMT-SL: Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Centre Hospitalier Universitaire de Nīmes | Not yet recruiting --> Recruiting | Initiation date: Dec 2025 --> Mar 2026
    Enrollment open • Trial initiation date
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    27d
    Tirbaso: Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Centre Hospitalier Universitaire de Nice | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    27d
    Primary adenoid cystic carcinoma (basal cell type) of the prostate: a case report. (PubMed, Discov Oncol)
    This case highlights the importance of recognizing this rare tumor in patients with prostatic mass and normal PSA, with diagnosis relying on characteristic histomorphology and immunophenotype.
    Journal
    |
    TP63 (Tumor protein 63)